Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hedge Fund Seeks Higher Price For Qiagen As COVID-19 Boosts Sales

Executive Summary

Hedge fund Davidson Kempner advised Qiagen to ask for a higher acquisition price from Thermo Fisher Sciences as COVID-19 has increased demand for diagnostic products.

You may also be interested in...



Qiagen Ready To Rival Abbott With Rapid, Portable Antigen COVID-19 Test

The diagnostics company said the test is scheduled for US launch in Q4 2020.

Qiagen Terminates Thermo Fisher Deal After Shareholders Reject Last Offer

Qiagen's shareholders said Thermo Fisher's final offer price for the diagnostics company was too low.

Thermo Fisher Scientific Announces $11.5Bn Buyout Of Qiagen

Thermo Fisher expects the deal to improve its portfolio of specialty diagnostics for clinical labs while its genetic analysis technologies, biosciences reagents and consumable products will complement Qiagens’ sample preparation and assay technologies.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1129947

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel